DR. PAUL ALFRED GURBEL, M.D.
Osteopathic Medicine at Belvedere Ave, Baltimore, MD

6552014, Apr 22, 2003

Mar 12, 2001

09/804689

Victor L. Serebruany - Ellicott City MD
Paul A. Gurbel - Baltimore MD
Christopher M. OConnor - Durham NC

HeartDrug Research, L.L.C. - Ellicott City MD

A61K 3155

51421402, 514217, 51425213, 51425405, 51425407, 514315, 514438, 514653, 514656, 514657

The present invention pertains to methods for reducing the platelet activation state in an individual comprising administering a selective serotonin reuptake inhibitor (SSRI). The platelet activation state is reduced upon administering a SSRI, as measured by one or more platelet activation markers. The invention also relates to methods for treating or preventing an individual at risk for a vascular event, disease or disorder by administering a SSRI.

8070678, Dec 6, 2011

Oct 4, 2006

11/663599

Paul A. Gurbel - Baltimore MD, US

A61B 5/00

600369

A method of selecting a stent for implantation in the circulatory system of a human being includes the steps of determining a threshold level of platelet hyper-coaguability (PHC). One marker of PHC is platelet-fibrin mediated clot strength (MA) of blood. MA above a threshold demonstrates a risk of restenosis that is relatively high. In practicing the method, a sample of blood is obtained from a patient who requires implantation of a stent, the blood sample is tested for its platelet-fibrin mediated clot strength, the clot strength of the blood sample is compared with the threshold level; if the blood sample has a clot strength below the threshold level, selecting a bare metal stent, and if the blood sample has a clot strength at or above the threshold level, selecting a drug-eluting stent. The method includes, in a preferred embodiment, use of a viscoelastic monitor to perform the testing step. Other markers of PHC may also be employed such as measurement of thrombin generation and/or platelet reactivity.

2012026, Oct 18, 2012

Dec 1, 2011

13/309121

Paul A. Gurbel - Baltimore MD, US

G01N 33/86, C12Q 1/56

435 13, 436 63

Provided is a method of selecting a stent for implantation in the circulatory system of a human being. The method comprises obtaining a blood sample from a patient who requires implantation of a stent and testing said blood sample to determine a platelet coagulability level. The determined platelet coagulability level of said blood sample is compared with a threshold level of blood platelet coagulability. A determined platelet coagulability level above said threshold level indicates that a risk of restenosis is relatively high. If the determined platelet coagulability level is below said threshold level, a bare metal stent is selected. If the determined platelet coagulability level is at or above said threshold level, a drug-eluting stent is selected.

8440420, May 14, 2013

Nov 7, 2011

13/290377

Paul A. Gurbel - Baltimore MD, US

C12Q 1/56

435 13, 435214, 435217

The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis.

6230713, May 15, 2001

Jan 29, 1998

9/015385

Margaret R. Dalesandro - Devon PA
Paul A. Gurbel - Baltimore MD
Victor L. Serebruany - Ellicott City MD

A61B 1900

128898

A treatment plan for patients suffering from a thrombotic event can be determined by measuring membrane bound and/or soluble P-selectin. The degree of reperfusion can be determined by assessing the level of soluble P-selectin subsequent to reperfusion. Additionally, predicting whether thrombolytic therapy will induce reperfusion can be determined by measuring the level of membrane bound P-selectin prior to reperfusion.

6245782, Jun 12, 2001

May 17, 1999

9/312987

Victor L. Serebruany - Ellicott City MD
Paul A. Gurbel - Baltimore MD
Christopher M. O'Connor - Durham NC

Heartdrug Research L.L.C. - Ellicott City MD

A61K 31445, A61K 3134, A61K 3115, A61K 31135, A61K 3103

514321

The present invention pertains to methods for reducing the platelet activation state in an individual comprising administering a selective serotonin reuptake inhibitor (SSRI). The platelet activation state is reduced upon administering a SSRI, as measured by one or more platelet activation markers. The invention also relates to methods for treating or preventing an individual at risk for a vascular event, disease or disorder by administering a SSRI.

5295959, Mar 22, 1994

Mar 13, 1992

7/850638

Paul A. Gurbel - Baltimore MD
R. David Anderson - Baltimore MD

Medtronic, Inc. - Minneapolis MN

A61M 2900

604 96

An autoperfusion dilatation catheter useful in angioplasty comprises a conventional catheter shaft and an inflatable balloon. The catheter is designed such that the balloon, when inflated, has an outer surface relief-structure whereby when this outer surface is fully inflated and exerts pressure on the inner surface of a blood vessel, blood continues to flow between the outer surface of the balloon and the blood vessel surface. Preferably, the relief structure is a channel formed in the outer surface of the balloon by the pressure of a band attached to the catheter and which presses against the outer surface of the balloon.

7381536, Jun 3, 2008

Mar 1, 2005

11/070845

Paul A. Gurbel - Baltimore MD, US

C12Q 1/56

435 13

The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis.